



UNIVERSITÀ
DEGLI STUDI
FIRENZE

FLORE

Repository istituzionale dell'Università degli Studi di Firenze

Radiologic Cerebral Reperfusion at 24 h Predicts Good Clinical Outcome

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

Radiologic Cerebral Reperfusion at 24 h Predicts Good Clinical Outcome / Carbone, Federico*; Busto, Giorgio; Padroni, Marina; Bernardoni, Andrea; Colagrande, Stefano; Dallegri, Franco; Montecucco, Fabrizio; Fainardi, Enrico. - In: TRANSLATIONAL STROKE RESEARCH. - ISSN 1868-4483. - ELETTRONICO. - 10:(2019), pp. 178-188. [10.1007/s12975-018-0637-8]

Availability:

The webpage <https://hdl.handle.net/2158/1134811> of the repository was last updated on 2019-07-20T17:04:25Z

Published version:

DOI: 10.1007/s12975-018-0637-8

Terms of use:

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

Publisher copyright claim:

La data sopra indicata si riferisce all'ultimo aggiornamento della scheda del Repository FloRe - The above-mentioned date refers to the last update of the record in the Institutional Repository FloRe

(Article begins on next page)

Radiologic cerebral reperfusion at 24 hours predicts good clinical outcome

Federico Carbone MD, PhD¹, Giorgio Busto MD², Marina Padroni MD³, Andrea Bernardoni MD⁴, Stefano Colagrande MD², Franco Dallegri MD^{1,5}, Fabrizio Montecucco MD, PhD^{1,5,6}, Enrico Fainardi, MD, PhD⁷.

¹ First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa School of Medicine, 6 viale Benedetto XV, 13132 Genoa, Italy. ²Struttura Organizzativa Dipartimentale di Radiodiagnostica 2, Dipartimento di Scienze Biomediche, Sperimentali e Cliniche, Università degli Studi di Firenze, Azienda Ospedaliero-Universitaria Careggi, 3 Largo Brambilla, 50134 Florence, Italy. ³Unità Operativa di Neurologia, Dipartimento di Scienze Biologiche, Psichiatriche e Psicologiche, Università di Ferrara, Arcispedale S. Anna, Ferrara, Italy. ⁴Unità Operativa di Neuroradiologia, Dipartimento di Neuroscienze, Azienda Ospedaliero-Universitaria di Ferrara, Arcispedale S. Anna, 203 Corso della Giovecca, 44121 Ferrara, Italy. ⁵Ospedale Policlinico San Martino, 10 Largo Benzi, 16132 Genoa, Italy. ⁶Centre of Excellence for Biomedical Research (CEBR), University of Genoa, 9 viale Benedetto XV, 16132 Genoa, Italy. ⁷Struttura Organizzativa Dipartimentale di Neuroradiologia, Dipartimento di Scienze Biomediche, Sperimentali e Cliniche, Università degli Studi di Firenze, Azienda Ospedaliero-Universitaria Careggi, 3 Largo Brambilla, 50134 Florence, Italy.

Running title: complete reperfusion and stroke outcome

Key words: ischemic stroke, reperfusion, recanalization, ischemic core, penumbra, inflammation.

Corresponding author: Federico Carbone, MD, PhD. First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa School of Medicine, 6 viale Benedetto XV, 13132 Genova. Tel: +39 010 353 7940; Fax: +39 010 353 8686; E mail: federico.carbone@edu.unige.it

Abstract

Background: cerebral reperfusion and arterial recanalization are radiological features of the effectiveness of thrombolysis in acute ischemic stroke (AIS) patients. Here, an investigation of the prognostic role of early recanalization/reperfusion on clinical outcome was performed.

Methods: In AIS patients (n=55), baseline computerized tomography (CT) was performed ≤ 8 hours from symptom onset, whereas CT determination of reperfusion/recanalization was assessed at 24 hours. Multiple linear and logistic regression models were used to correlate reperfusion/recanalization with radiological (i.e. hemorrhagic transformation, ischemic core and penumbra volumes) and clinical outcomes (assessed as National Institutes of Health Stroke Scale [NIHSS] reduction ≥ 8 points or a NIHSS ≤ 1 at 24 hours and as modified Rankin Scale [mRS] < 2 at 90 days).

Results: At 24 hours, patients achieving radiological reperfusion were n=24, while the non-reperfused were n=31. Among non-reperfused, n=15 patients were recanalized. Radiological reperfusion vs. recanalization was also confirmed by early increased levels of circulating inflammatory biomarkers (i.e. serum osteopontin). In multivariate analysis, ischemic lesion volume reduction was associated with both recanalization ($\beta=0.265$; $p=0.014$) and reperfusion ($\beta=0.461$; $p<0.001$), but only reperfusion was independently associated with final infarct volume ($\beta=-0.333$; $p=0.007$). Only radiological reperfusion at 24 hours predicted good clinical response at day 1 (adjusted OR 16.054 [1.423-181.158]; $p=0.025$) and 90-day good functional outcome (adjusted OR 25.801 [1.483-448.840]; $p=0.026$). At ROC curve analysis the AUC of reperfusion was 0.777 ($p<0.001$) for the good clinical response at 24 hours and 0.792 ($p<0.001$) for 90-day clinical outcome.

Conclusion: 24-hour radiological reperfusion assessed by CT is associated with good clinical response on day 1 and good functional outcome on day 90 in patients with ischemic stroke.

Key words: ischemic stroke, reperfusion, recanalization, ischemic core, penumbra, inflammation.

1. Introduction

The early pharmacological or mechanical restoration of the blood flow in the ischemic brain is recommended to treat acute ischemic stroke (AIS) [1, 2]. The effectiveness of thrombolysis is mainly driven by the establishment of early recanalization and/or reperfusion [3]. Although they are closely related, these pathophysiological conditions can be radiologically identified. For instance, thrombolysis may fail to induce recanalization [4, 5], but reperfusion may be maintained by collateral circulation. In turn, successful recanalization does not consistently lead to reperfusion in case of distal thrombus embolization [6] or no-reflow phenomenon [7]. Despite these pathophysiological aspects, the term “recanalization” and “reperfusion” have been long-time used interchangeably [8]. Nowadays, advances in imaging methods have been applied to discriminate these entities. In addition, it is now possible to routinely visualize the ischemic core, the penumbral tissue and the state of collateral blood supply. Recently, the clinical benefit of recanalization achieved by endovascular treatment was demonstrated in seven clinical trials, whereas the prognostic relevance of reperfusion in predicting improved clinical and radiological outcome was reported in some of these and other clinical trials [9-12]. This study, enrolling patients with AIS and undergoing serial examination with computerized tomography (CT), has been designed to compare the prognostic value of reperfusion vs. recanalization after an AIS. Whereas long term (day 90) good functional outcome was set as primary endpoint we have also planned to investigate potential correlations between reperfusion and serum inflammatory biomarkers.

2. Methods

2.1 Patients selection and clinical assessment

We retrospectively analyzed clinical and radiological data from n=55 consecutively AIS patients admitted to the Neuroscience Department of Ferrara University Hospital during the period from April 2016 to December 2017. All patients were treated according with the current guidelines [13, 14]. Inclusion criteria were: i) presentation at the hospital within 8 hours from symptom onset; ii) baseline and follow-up confirmation of a large vessel anterior AIS based on CT findings represented by the absence of intracranial hemorrhage on Non-contrast CT (NCCT) at admission, the presence of a territorial hypoperfused area on CT perfusion (CTP) at onset and the presence of a territorial hypoattenuated area on NCCT at 24 hours; iii) baseline and follow-up CT imaging carried out at established time-points after symptom onset (NCCT, CT angiography [CTA] and CTP at admission, NCCT, CTA and CTP at days 1 and NCCT at day 90). Exclusion criteria included: the detection of brain stem infarct or intracerebral hemorrhage at admission NCCT, the inability to complete multimodal CT

protocol at baseline and follow-up, history of strokes with residual deficit; contraindications to iodinated contrast agent, pregnancy, age <18 years, clinical instability and/or poor quality of CT acquisition due to motion artifacts. Lacunar AIS were also excluded, due to the low sensitivity of CTP in detecting them [15, 16]. To select a more homogenous population, we further excluded minor strokes (defined by a NIHSS <4) as well as patients receiving intra-arterial thrombolysis and mechanical thrombectomy. As previously reported [17], we further excluded patients with lacunar/undetermined or posterior circulation stroke, NIHSS <4 at enrollment and those receiving intra-arterial thrombolytic therapy as well. Type of reperfusion therapy (if any) was recorded. The Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria were used to categorize AIS subtypes. [18], whereas the National Institutes of Health Stroke Scale (NIHSS) was used to score the disease severity at onset, day 1, and day 90 after AIS [19]. The Local Ethics Committee approved this study, in accordance with the guidelines of the Declaration of Helsinki. The All patients gave informed consent before entering in the study.

2.2 Study endpoint and power estimation

The primary endpoint was to determine whether the occurrence of radiological reperfusion might predict long term (day 90) good functional outcome, defined as a modified Rankin scale (mRS) at day 90 <2 [17, 20, 21]. The sample size was computed based on an expected prevalence of complete reperfusion of 45%, taking into account a prevalence of good functional outcome of 65% and a minimum of six-fold increased incidence in reperfused patients [17, 21]. According with our power calculation for two proportion comparison, the minimum sample size requested to detect a six-fold increase in the incidence of good functional outcome with a power of 80% and with a two-sided alpha error of 5% was of 12 patients. As secondary endpoint, we investigated the ability of reperfusion to predict early favourable clinical response, defined as a reduction of ≥ 8 points on the NIHSS [17] during the first day after AIS, and the occurrence of haemorrhagic transformation during the first 7 days after AIS. Finally, potential correlations between reperfusion and serum biomarkers of inflammation has been explored. Two blinded independent investigators adjudicated the study endpoints.

2.3 Imaging acquisition protocol

All images were conducted on 64-slice scanners and included i) NCCT carried out from the skull base to the vertex; ii) CTA performed from the carotid bifurcation to vertex; iii) CTP that covered a total of 4 cm from the basal ganglia to the lateral ventricles. CTP studies were obtained with a dynamic first-pass bolus-tracking methodology according to a one-phase imaging protocol consisting of an acquisition of 50-seconds continuous

(cine) scans, which started 5 seconds after the automatic injection of 40 ml of non-ionic contrast agent at the rate of 4 ml/sec.

2.4 *Imaging processing and analysis*

According to EXTEND-IA trial [22], the severity of arterial occlusion was judged on CTA at onset using a modified version of the Thrombolysis in Myocardial Infarction (TIMI) grading system: complete occlusion (TIMI score=0-1); partial occlusion (TIMI score=2); no occlusion (TIMI score=3). Patients with TIMI score ranging between 0 and 1 were categorized as occluded, whereas a TIMI score of 2 and 3 defined the not occluded ones. The site of occlusion was assessed as previously indicated [23]. All CTP scans were assessed using a commercially available delay-sensitive deconvolution software (CT Perfusion 3, GE Healthcare, Waukesha, WI). For each CTP scan, time-density curves for the arterial input function and venous output functions were obtained from the anterior cerebral artery and superior sagittal sinus, respectively. The AIF was corrected for partial volume averaging using the VOF-TDC. Cerebral blood flow (CBF), cerebral blood volume (CBV) and mean-transit-time (MTT) CTP maps were generated for each patient by deconvolution of tissue TDCs and the AIF. CBF, CBV and MTT values were expressed in ml/min/100g, ml/100g and seconds, respectively. Large blood vessels were automatically excluded from calculation by the software. Color coded functional CTP map scales were set at 0-100 ml/min/100g for CBF, 0-8 ml/100g for CBV and 0-20 seconds for MTT. After identification by visual inspection on MTT and CBV maps, three different regions of interest (ROIs) were drawn freehand by two neuroradiologists (A.B. and E.F., with 5- and 20-year experience, respectively) on every section in which they were visible according to the classical CTP mismatch model [24]: i) MTT lesion indicating total hypoperfusion; ii) CBV lesion referring to infarct core; iii) MTT-CBV lesion representing ischemic penumbra (Figure 1). This last ROI was outlined on MMT maps where the ROI corresponding to CBV defect were automatically superimposed. Discrepancies between readers were resolved by consensus adjudication. The sum of these lesion areas was then multiplied by slice thickness to obtain core and penumbra (CTP MTT-CBV mismatch) volumes, respectively. Final infarct volume was measured on follow-up NCCT at 3 months after symptom onset with a multi-slice planimetric method by summation of the hypodense areas, manually traced on each slice in which they were detectable, multiplied by slice thickness [25]. The type of HT was recorded by NCCT at 24 hours and at 7 days post ictus. In agreement with EXTEND-IA trial [22], recanalization was scored on CTA at 24 hours with an adaptation of the TIMI grading system: persistent occlusion (TIMI score=0-1); partial recanalization (TIMI score=2); full recanalization (TIMI score=3). Patients

with TIMI score ranging from 2 to 3 were considered as recanalized, whereas patients with TIMI score of 0 and 1 were classified as not recanalized. All patients not occluded on CTA at admission had a TIMI score of 3 at 24 hour-CTA and therefore, were considered as recanalized. Radiological reperfusion was evaluated by reperfusion index that measures the percentage reduction of baseline MTT lesion at 24 hours. For this purpose, visually identified MTT defect volume was obtained by a manual multi-slice planimetric method at admission and at 24 hours [26]. Patients with a reperfusion index >75% were considered as reperfused. Reduction of the ischemic volume was expressed as the difference between total hypoperfusion volumes at admission (baseline) and at 24 hours.

2.5 Blood collection and quantification

Blood samples were collected at different time points using a butterfly to reduce membrane shear stress and then drawn in tubes to obtain serum. Samples were collected at baseline and at day 1 after AIS. Hematology parameters and blood chemistry, including plasma glucose, triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein cholesterol (to assess dyslipidemia) were measured by routine auto-analyzer.

2.6 Measurement of a serum biomarker associated with reperfusion

Serum osteopontin (OPN), a biomarker associated with cerebral reperfusion [27, 28], were measured by colorimetric enzyme-linked immunosorbent assay (ELISA), following manufacturer's instructions (R&D Systems, Minneapolis, MN). The limits of detection for OPN was 62.5 pg/ml. Mean intra- and inter-assay coefficients of variation (CV) were below 8% for all markers [29].

2.7 Statistical analysis

Analyses were performed with IBM SPSS Statistics for Windows, Version 23.0 (IBM CO., Armonk, NY). Categorical data are presented as relative and absolute frequencies. Continuous variables were expressed as median and interquartile range (IQR) as the normality assumption was not demonstrated. Difference between two time-points were presented as delta (Δ). Intergroup comparisons were drawn by Fisher's exact test and Mann-Whitney *U*-test, as appropriate. Conversely, the dichotomized classification of reperfusion and recanalization was compared by McNemar test. Instead comparison between paired sample was drawn by Wilcoxon rank sum test. Multiple linear regressions were performed to model the lesion growth and

final infarct volumes with the recanalization and reperfusion. Multivariate logistic regression was used to evaluate the predictive role of recanalization and reperfusion toward good clinical response and good functional outcome. Finally, the prognostic ability was assessed in a post-hoc manner based upon receiver operator characteristic (ROC) curve (MedCalc 12.5, MedCalc Software, Ostend, Belgium). The area under the curve (AUC) was given with 95% confidence interval (CI). For all statistical analyses a 2-sided p-value <0.05 was considered as statistically significant.

3 Results

3.1 Patients' characteristics

Baseline clinical characteristics of the whole cohort (n=55) are listed in Table 1. Patients' median age was 69 years (55-76), with a slight prevalence of hypertension (58.2%). In most cases the time window between symptom onset and CT study performed was less than 3 hours (81.8%), thus accounting for a high rate of reperfusion therapy with r-tPA (70.9%). More precisely, in our study population, 49/55 (89.1%) patients were treated (n=39 with intravenous thrombolysis with r-tPA and n=10 with mechanical thrombectomy), whereas 6/55 (10.9%) did not receive any therapy due to the presence of hypodensity >1/3 cerebral hemisphere, as indicated by ASPECTS<7, on admission NCCT (n=3), and the current use of anticoagulant with INR>1.7 (n=3). At day 1 after AIS, reperfusion was present in 24 patients (43.6%). (Table 2). In 15 patients (27.3%) there was a pattern characterized by recanalization without reperfusion (Table 2). Conversely, no patients had reperfusion without recanalization, whereas in 24 patients (43.6%) both reperfusion and recanalization were observed. A McNemar test on the dichotomized classification of reperfusion and recanalization confirmed a significant discrepancy between these two parameters ($p<0.001$) (Table 2).

3.2 *Reperfusion and recanalization weakly influences inflammatory biomarkers and radiological features of cerebral injury*

Ischemic core and penumbra volumes did not differ in patients categorized as recanalized vs. non-recanalized and reperfused vs. non-reperfused (Figure 2A-C). Conversely, reperfusion determined a great reduction of the ischemic volume during the first day after AIS (Δ baseline-day 1: 78.59 vs. 14.59 ml; $p<0.001$). A lesser but significant benefit was also observed in the group of recanalized patients (Δ baseline-day 1: 37.95 vs. 13.30 ml; $p=0.025$). OPN was tested as a known circulating mediators increased after cerebral reperfusion [27, 28]. Noteworthy, when non-reperfused and reperfused patients were analyzed separately, no difference was shown in

demographic, biochemical and clinical/radiological parameters (Table 3). Whereas no difference was observed at baseline, a significant increase was observed the day after AIS ($p=0.002$), thus determining a significant difference among the two study groups ($p=0.004$) (Figure 3). Multilinear regression analysis further confirmed an independent association of volume lesion reduction at day 1 with both recanalization (29.425 [6.271-52.580]; $\beta=0.265$; $p=0.014$) and reperfusion (B 46.803 [95% CI 29.138-64.469]; $\beta=0.461$; $p<0.001$) (Table 4). However, only the reperfusion was independently associated with final infarct volume at day 90 after AIS (B -54.236 [95% CI 93.203- -15.270]; $\beta= -0.333$; $p=0.007$) (Table 4).

3.3 *Reperfusion at 24 hours is a strong predictor of good outcome after an AIS*

Reperfusion, but not recanalization, was able to predict good clinical response at 24 hours also after adjustments for age, gender, glycaemia, time window to CT, intravenous thrombolysis, NIHSS, ischemic core and penumbra volumes at onset (OR 16.054 [1.423-181.158]; $p=0.025$) (Table 5). Though non-significant, reperfusion shown a trend towards the prediction of hemorrhagic transformation during the first 7 day after AIS (adjusted OR 0.153 [0.022-1.047]; $p=0.056$) (Table 5). However, the most relevant result was the predictive ability of reperfusion towards 90-day good functional outcome, assessed by mRS (adjusted OR 25.801 [1.483-448.840]; $p=0.026$) (Table 5). ROC curve analysis, further characterized the predictive ability of reperfusion by showing an AUC of 0.777 (sensitivity 88.89%, specificity 64.86%; $p<0.001$) and 0.792 (sensitivity 88.89%, specificity 75.68%; $p<0.001$) for the good clinical response and good long-term clinical outcome, respectively (Figure 4).

4 Discussion

In this study, reperfusion at 24 hours after AIS consistently overcame recanalization in predicting radiological evolution of ischemic lesion and clinical outcomes. Indeed, patients with MTT reperfusion index $>75\%$ experienced a greater reduction of ischemic lesion volume during the first day after AIS and a smaller infarct volume at 90 days. According with radiological findings, reperfusion was also associated to more favorable prognosis in terms of good clinical response at 24 hours and good functional outcome assessed 90 days after AIS. Noteworthy, we observed some discrepancies between recanalization and reperfusion rates. As compared to previous studies [17, 26], we did not observe reperfusion without recanalization, whereas the recanalization occurred without reperfusion in fifteen patients. This implies that, in some cases, reopening of the occluded artery is not associated with the restoration of microcirculatory blood flow [4]. On the other hand, it is important to emphasize that reperfusion can be non-nutritional inducing a luxury perfusion, exceeding metabolic demand,

in non-viable tissue evolving into infarct [30] or a deterioration of ischemic but salvageable brain tissue due to an impairment of neurovascular unit mediated by molecular and cellular mechanisms [31]. Nevertheless, the present study further emphasizes a conceptual difference between reperfusion and recanalization. The discrepancy between angiographically successful recanalization and non-favorable clinical outcome might be explained by a non-visible alteration in microcirculation, as occurs in case of distal thrombus embolization [6] or no-reflow phenomenon. In the latter case, swollen astrocyte, pericyte and endothelial cells determine the narrowing of microvascular lumen and failure of microcirculatory reperfusion despite clot removal [32, 33]. The capillary narrowing usually starts one hour after AIS and contributes to brain injury by promoting oxidative stress [32]. Not surprisingly, more recent experimental studies [34] and clinical trials [35, 36] pointed out the role of early (or even ultra-early) reperfusion as key determinant of stroke outcome [5, 37, 38]. Our results are then consistent with previous studies based on both CT [26] and magnetic resonance [39-41], in supporting a role of reperfusion as surrogate marker of clinical outcome independently of recanalization. More specifically, we emphasized the role of earlier repeated follow-up imaging in improving the prognostic value of reperfusion [42]. Another critical matter of discussion is the role of inflammation in ischemic/reperfusion (I/R) injury [43]. Various studies in the last decade emphasized the detrimental role of inflammatory response in AIS. We previously observed that delayed rise in serum OPN was associated with poor long-term clinical outcome after an AIS [44]. Similarly, time-dependent changes in serum OPN were also correlated with left-ventricular volume and function in patients with myocardial infarction undergoing successful reperfusion [45]. Yet, numerous clinical studies failed to demonstrate any positive outcomes of anti-inflammatory strategies in stroke patients [46]. Rather, the timing of inflammatory response is increasingly emerging as main determinant of I/R injury outcome. Whereas persistent inflammation exerts negative effects on tissue repair, early inflammatory response seems to drive tissue healing [47]. With this aim we focused on the early change in circulating OPN, reporting a significant rise in reperfused patients. Nevertheless, long-term kinetic of OPN after AIS and potential relationship with radiological findings still remains unknown and any potential explanation is highly speculative.

5 Study limitations

Firstly, the study cohort may not be considered representative of a general stroke population as whole and future population-based studies are warranted to validate our results. Whereas we were able to demonstrate the prognostic role of reperfusion independently of intravenous thrombolysis, our sample size was not powerful enough to discriminate the effect of other therapeutic approaches (i.e. intra-arterial thrombolysis and mechanical

thrombectomy). Similarly, larger studies are required to investigate the setting of minor stroke, where the expected differences may be smaller. Secondly, recanalization/reperfusion imaging was obtained relatively late, and recanalization/reperfusion observed at 24 hours after AIS may not have the ability to salvage viable ischemic tissue at risk. However, the time from admission to recanalization/reperfusion imaging and to discharge imaging was similar for all patients, thus not introducing a bias in the analysis. Thirdly, the evaluation of reperfusion by CTP is incomplete because this technique is not able to obtain metabolic information which are crucial, in combination with hemodynamic parameters, to establish whether the restoration of microvascular circulation corresponds to an actual tissue recovery or leads to reperfusion injury [48]. In this way, only positron emission tomography can provide both hemodynamic and metabolic data useful to better understand tissue fate [49]. Fourthly, the estimation of final infarct volume with 24 hour NCCT could be affected by a distortion of residual cavity due to retraction effects related to gliosis. However, it is currently accepted that final infarct volume is more accurately delineated in images obtained 30 or 90 days after stroke [50]. Fifthly, it is well-known that threshold-based fully-automated software are superior to manually tracing technique we used in this study for quantitative volumetric analysis of CBV and MTT alterations [51]. Nevertheless, the calculation of CBV and MTT lesion volume by a manual multi-slice planimetric method is still considered reliable in defining core and penumbra [52] and reperfusion on CTP [53]. Finally, different studies have described a bi-modal delayed peak of OPN (a serum biomarker associated with reperfusion) after AIS [54]. Therefore, future prospective cohorts should include earlier and later time points in order to able to correlate radiological evolution (in terms of recanalization/reperfusion) with overtime change in circulating OPN.

6 Conclusion

In conclusion, we were able to show that reperfusion occurring during the first day after AIS in predicting better radiological evolution of ischemic lesion and clinical outcome. Also, reperfusion, but not recanalization was associated with an increase in serum levels of OPN, an inflammatory molecule potentially related with post-ischemic cerebral pathophysiology. Future studies correlating radiological reperfusion and potential biomarkers are warranted to investigate the fine-tuned mechanisms underlying cerebral ischemia/reperfusion salvage.

Funding

Analysis and interpretation of data were supported by a grant from the European Commission to Prof F. Mach (FP7-INNOVATION I HEALTH-F2-2013-602114).

Compliance with Ethical Standards

Conflict of interest

Federico Carbone declares that he has no conflict of interest.

Giorgio Busto declares that he has no conflict of interest.

Marina Padroni declares that she has no conflict of interest.

Andrea Bernardoni declares that he has no conflict of interest.

Stefano Colagrande declares that he has no conflict of interest.

Franco Dallegri declares that he has no conflict of interest.

Fabrizio Montecucco declares that he has no conflict of interest.

Enrico Fainardi declares that he has no conflict of interest.

Research involving human participants and/or animals

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent was obtained from all individual participants included in the study.

This article does not contain any studies with animals performed by any of the authors.

References

1. Bhaskar S, Stanwell P, Cordato D, Attia J, Levi C: Reperfusion therapy in acute ischemic stroke: dawn of a new era? *BMC Neurol* 2018, 18(1):8.
2. Powers WJ, Rabinstein AA, Ackerson T, *et al*: 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke* 2018, 49(3):e46-e110.
3. El Amki M, Wegener S: Improving Cerebral Blood Flow after Arterial Recanalization: A Novel Therapeutic Strategy in Stroke. *Int J Mol Sci* 2017, 18(12).
4. Horsch AD, Dankbaar JW, Niesten JM, *et al*: Predictors of reperfusion in patients with acute ischemic stroke. *AJNR Am J Neuroradiol* 2015, 36(6):1056-1062.
5. Iglesias-Rey R, Rodriguez-Yanez M, Rodriguez-Castro E, *et al*: Worse Outcome in Stroke Patients Treated with rt-PA Without Early Reperfusion: Associated Factors. *Transl Stroke Res* 2017.
6. Janjua N, Alkawi A, Suri MF, Qureshi AI: Impact of arterial reocclusion and distal fragmentation during thrombolysis among patients with acute ischemic stroke. *AJNR Am J Neuroradiol* 2008, 29(2):253-258.
7. Bouleti C, Mewton N, Germain S: The no-reflow phenomenon: State of the art. *Arch Cardiovasc Dis* 2015, 108(12):661-674.
8. Tomsick T: TIMI, TIBI, TICI: I came, I saw, I got confused. *AJNR Am J Neuroradiol* 2007, 28(2):382-384.
9. Saver JL, Goyal M, Bonafe A, *et al*: Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N Engl J Med* 2015, 372(24):2285-2295.
10. Campbell BCV, Donnan GA, Lees KR, *et al*: Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke. *Lancet Neurol* 2015, 14(8):846-854.
11. Nogueira RG, Jadhav AP, Haussen DC, *et al*: Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. *N Engl J Med* 2018, 378(1):11-21.
12. Albers GW, Marks MP, Kemp S, *et al*: Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. *N Engl J Med* 2018, 378(8):708-718.
13. Jauch EC, Saver JL, Adams HP, Jr., *et al*: Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2013, 44(3):870-947.
14. Powers WJ, Derdeyn CP, Biller J, *et al*: 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke* 2015, 46(10):3020-3035.
15. Benson JC, Payabvash S, Mortazavi S, *et al*: CT Perfusion in Acute Lacunar Stroke: Detection Capabilities Based on Infarct Location. *AJNR Am J Neuroradiol* 2016, 37(12):2239-2244.
16. Morelli N, Rota E, Michieletti E, Guidetti D: The "Vexata Quaestio" on Lacunar Stroke: The Role of CT Perfusion Imaging. *AJNR Am J Neuroradiol* 2017, 38(2):E11-E12.
17. Cho TH, Nighoghossian N, Mikkelsen IK, *et al*: Reperfusion within 6 hours outperforms recanalization in predicting penumbra salvage, lesion growth, final infarct, and clinical outcome. *Stroke* 2015, 46(6):1582-1589.
18. Adams HP, Jr., Bendixen BH, Kappelle LJ, *et al*: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke* 1993, 24(1):35-41.
19. Brott T, Adams HP, Jr., Olinger CP, *et al*: Measurements of acute cerebral infarction: a clinical examination scale. *Stroke* 1989, 20(7):864-870.
20. Katzan IL, Lapin B: PROMIS GH (Patient-Reported Outcomes Measurement Information System Global Health) Scale in Stroke: A Validation Study. *Stroke* 2018, 49(1):147-154.
21. Dargazanli C, Arquizán C, Gory B, *et al*: Mechanical Thrombectomy for Minor and Mild Stroke Patients Harboring Large Vessel Occlusion in the Anterior Circulation: A Multicenter Cohort Study. *Stroke* 2017, 48(12):3274-3281.
22. Campbell BC, Mitchell PJ, Kleinig TJ, *et al*: Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med* 2015, 372(11):1009-1018.
23. Higashida RT, Furlan AJ, Roberts H, *et al*: Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. *Stroke* 2003, 34(8):e109-137.
24. Wintermark M, Flanders AE, Velthuis B, *et al*: Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. *Stroke* 2006, 37(4):979-985.
25. Brott T, Marler JR, Olinger CP, *et al*: Measurements of acute cerebral infarction: lesion size by computed tomography. *Stroke* 1989, 20(7):871-875.

26. Soares BP, Tong E, Hom J, *et al*: Reperfusion is a more accurate predictor of follow-up infarct volume than recanalization: a proof of concept using CT in acute ischemic stroke patients. *Stroke* 2010, 41(1):e34-40.
27. Choi JS, Kim HY, Cha JH, Choi JY, Lee MY: Transient microglial and prolonged astroglial upregulation of osteopontin following transient forebrain ischemia in rats. *Brain Res* 2007, 1151:195-202.
28. Baliga SS, Merrill GF, Shinohara ML, Denhardt DT: Osteopontin expression during early cerebral ischemia-reperfusion in rats: enhanced expression in the right cortex is suppressed by acetaminophen. *PLoS One* 2011, 6(1):e14568.
29. Carbone F, Rigamonti F, Burger F, *et al*: Serum levels of osteopontin predict major adverse cardiovascular events in patients with severe carotid artery stenosis. *Int J Cardiol* 2018, 255:195-199.
30. Nagar VA, McKinney AM, Karagulle AT, Truwit CL: Reperfusion phenomenon masking acute and subacute infarcts at dynamic perfusion CT: confirmation by fusion of CT and diffusion-weighted MR images. *AJR Am J Roentgenol* 2009, 193(6):1629-1638.
31. Pan J, Konstas AA, Bateman B, Ortolano GA, Pile-Spellman J: Reperfusion injury following cerebral ischemia: pathophysiology, MR imaging, and potential therapies. *Neuroradiology* 2007, 49(2):93-102.
32. Yemisci M, Gursoy-Ozdemir Y, Vural A, Can A, Topalkara K, Dalkara T: Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. *Nat Med* 2009, 15(9):1031-1037.
33. Ito U, Hakamata Y, Kawakami E, Oyanagi K: Temporary [corrected] cerebral ischemia results in swollen astrocytic end-feet that compress microvessels and lead to delayed [corrected] focal cortical infarction. *J Cereb Blood Flow Metab* 2011, 31(1):328-338.
34. Tachibana M, Ago T, Wakisaka Y, *et al*: Early Reperfusion After Brain Ischemia Has Beneficial Effects Beyond Rescuing Neurons. *Stroke* 2017, 48(8):2222-2230.
35. Saver JL, Jahan R, Levy EI, *et al*: Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. *Lancet* 2012, 380(9849):1241-1249.
36. Nogueira RG, Lutsep HL, Gupta R, *et al*: Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. *Lancet* 2012, 380(9849):1231-1240.
37. Angermaier A, Khaw AV, Kirsch M, Kessler C, Langner S: Influence of Recanalization and Time of Cerebral Ischemia on Tissue Outcome after Endovascular Stroke Treatment on Computed Tomography Perfusion. *J Stroke Cerebrovasc Dis* 2015, 24(10):2306-2312.
38. Golitz P, Muehlen I, Gerner ST, Knossalla F, Doerfler A: Ultraearly assessed reperfusion status after middle cerebral artery recanalization predicting clinical outcome. *Acta Neurol Scand* 2018. doi: 10.1111/ane.12907.
39. De Silva DA, Fink JN, Christensen S, *et al*: Assessing reperfusion and recanalization as markers of clinical outcomes after intravenous thrombolysis in the echoplanar imaging thrombolytic evaluation trial (EPITHET). *Stroke* 2009, 40(8):2872-2874.
40. Eilaghi A, Brooks J, d'Esterre C, *et al*: Reperfusion is a stronger predictor of good clinical outcome than recanalization in ischemic stroke. *Radiology* 2013, 269(1):240-248.
41. An H, Ford AL, Eldeniz C, *et al*: Reperfusion Beyond 6 Hours Reduces Infarct Probability in Moderately Ischemic Brain Tissue. *Stroke* 2016, 47(1):99-105.
42. Dankbaar JW, Horsch AD, van den Hoven AF, *et al*: Prediction of Clinical Outcome After Acute Ischemic Stroke: The Value of Repeated Noncontrast Computed Tomography, Computed Tomographic Angiography, and Computed Tomographic Perfusion. *Stroke* 2017, 48(9):2593-2596.
43. Kalogeris T, Baines CP, Krenz M, Korthuis RJ: Ischemia/Reperfusion. *Compr Physiol* 2016, 7(1):113-170.
44. Carbone F, Vuilleumier N, Burger F, *et al*: Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke. *Eur J Clin Invest* 2015, 45(6):579-586.
45. Suezawa C, Kusachi S, Murakami T, *et al*: Time-dependent changes in plasma osteopontin levels in patients with anterior-wall acute myocardial infarction after successful reperfusion: correlation with left-ventricular volume and function. *J Lab Clin Med* 2005, 145(1):33-40.
46. Mizuma A, Yenari MA: Anti-Inflammatory Targets for the Treatment of Reperfusion Injury in Stroke. *Front Neurol* 2017, 8:467.
47. Montecucco F, Liberale L, Bonaventura A, Vecchie A, Dallegri F, Carbone F: The Role of Inflammation in Cardiovascular Outcome. *Curr Atheroscler Rep* 2017, 19(3):11.
48. Nour M, Scalzo F, Liebeskind DS: Ischemia-reperfusion injury in stroke. *Interv Neurol* 2013, 1(3-4):185-199.
49. Marchal G, Young AR, Baron JC: Early postischemic hyperperfusion: pathophysiologic insights from positron emission tomography. *J Cereb Blood Flow Metab* 1999, 19(5):467-482.

50. Gaudinski MR, Henning EC, Miracle A, Luby M, Warach S, Latour LL: Establishing final infarct volume: stroke lesion evolution past 30 days is insignificant. *Stroke* 2008, 39(10):2765-2768.
51. Soares BP, Dankbaar JW, Bredno J, *et al*: Automated versus manual post-processing of perfusion-CT data in patients with acute cerebral ischemia: influence on interobserver variability. *Neuroradiology* 2009, 51(7):445-451.
52. Pezzini A, Busto G, Zedde M, *et al*: Vulnerability to Infarction During Cerebral Ischemia in Migraine Sufferers. *Stroke* 2018, 49(3):573-578.
53. Padroni M, Bernardoni A, Tamborino C, *et al*: Cerebral Blood Volume ASPECTS Is the Best Predictor of Clinical Outcome in Acute Ischemic Stroke: A Retrospective, Combined Semi-Quantitative and Quantitative Assessment. *PLoS One* 2016, 11(1):e0147910.
54. Shin YJ, Kim HL, Choi JS, Choi JY, Cha JH, Lee MY: Osteopontin: correlation with phagocytosis by brain macrophages in a rat model of stroke. *Glia* 2011, 59(3):413-423.

Figure Legend

Figure 1. Color coded functional CT perfusion map. After identification by visual inspection on mean-transit-time (MTT) and cerebral blood volume (CBV) maps, 3 different regions of interest were drawn freehand on every section according to the classical CTP mismatch model: **(A)** MTT lesion indicating total hypoperfusion; **(B)** CBV lesion referring to infarct core; **(C)** MTT-CBV lesion representing ischemic penumbra.

Figure 2. Box-whisker representative plots of the impact of recanalization/reperfusion of radiological findings. The values of ischemic core volume **(A)**, ischemic penumbra **(B)** and difference (Δ) in hypoperfused volume between onset at 24 hours **(C)** are represented in non-recanalized/recanalized and non-reperfused/reperfused patients.

Figure 3. Box-whisker representative plots of the modification in circulation osteopontin (OPN). Circulating OPN levels were quantified at baseline and after 1 day from stroke onset. Intergroup comparisons and overtime change were assayed.

Figure 4. Receiver operator characteristic (ROC) curve analysis. The predictive value of reperfusion toward good clinical response at 24 hours **(A)** and long-term functional outcome assessed by modified Rankin scale (mRS) at day 90 **(B)**.

Figure 1




Figure 2




Figure 3





Figure 4

A



B




Table 1. Clinical characteristics of study population (n=55) at admission.

Demographic	
Age, years (IQR)	69 (55-76)
Male, no (%)	29 (52.7)
Hypertension, no (%)	32 (58.2)
Atrial fibrillation, no (%)	23 (43.4)
Active smokers, no (%)	18 (33.3)
Previous smokers, no (%)	5 (9.1)
Diabetes, no (%)	4 (7.3)
Dyslipidemia, no (%)	13(23.6)
Biochemical	
Total WBC [#] , no. x 10 ⁹ (IQR)	7.91 (6.70-9.54)
Neutrophil count, no. x 10 ⁹ (IQR)	4.83 (3.71-6.74)
Lymphocyte count, no. x 10 ⁹ (IQR)	2.1 (1.53-2.58)
Serum glycaemia, mg/dL (IQR)	112 (97-143)
INR [*] , no. (IQR)	1.09 (1.02-1.19)
Clinical/ radiological	
Time window to CT [†]	
0-3 hours, no. (%)	45 (81.8)
3-6 hours, no. (%)	9 (16.4)
6-8 hours , no. (%)	1 (1.8)
TOAST [‡] classification	
Atherothrombotic, no. (%)	32 (58.2)
Cardio-embolic, no. (%)	23 (43.4)
Intravenous r-tPA [§] , no (%)	39 (70.9)
NIHSS	10 (7-14)
Total hypoperfused volume, ml (IQR)	88.03 (36.48-129.18)
Ischemic core volume, ml (IQR)	5.74 (0.51-17.18)
Ischemic penumbra, ml (IQR)	59.63 (27.04-102.32)

Data are expressed as median (interquartile range [IQR]) or number [no.] (percentages [%]).

WBC: white blood cells

* INR: international normalized ratio

† CT: computerized tomography

‡ TOAST: Trial of Org 10172 in Acute Stroke Treatment

§ r-tPA: recombinant tissue plasminogen activation

|| NIHSS: National Institutes of Health Stroke Scale

Table 2. Radiological characteristic at day 1.

		<i>p</i> -value
Reperfusion, n (%)	24 (43.6)	
Recanalization, n (%)	39 (70.9)	
Reperfusion vs. recanalization		<0.001
No-reperfusion, no-recanalization	16 (29.09)	
Recanalization without reperfusion (“no-reflow”) , n (%)	15 (27.3)	
Reperfusion without recanalization, n (%)	0 (0.0)	
Reperfusion and recanalization, n (%)	24 (43.6)	

Data are expressed as median (interquartile range [IQR]) or number [no.] (percentages [%]). Comparison was drawn by Fisher's exact test.

Table 3. Clinical differences among no-reperfused and reperfused patients at baseline.

	No-reperfused (n=31)	Reperfused (n=24)	p-value
Demographic			
Age, years (IQR)	67 (58-76)	71 (46-78)	0.939
Male, no (%)	17 (54.8)	12 (50.0)	0.789
Hypertension, no (%)	19 (61.3)	13 (54.2)	0.783
Atrial fibrillation, no (%)	12 (38.7)	11 (45.8)	0.783
Active smokers, no (%)	13 (41.9)	5 (21.7)	0.151
Previous smokers, no (%)	3 (9.7)	2 (8.3)	1.000
Diabetes, no (%)	3 (9.7)	1 (4.2)	0.624
Dyslipidemia, no (%)	10 (32.3)	3 (12.5)	0.116
Biochemical			
Total WBC [#] , no. x 10 ⁹ (IQR)	7.91 (6.99-10.01)	7.8 (6.26-9.01)	0.396
Neutrophil count, no. x 10 ⁹ (IQR)	5.11 (3.69-7.36)	4.45 (3.74-6.42)	0.665
Lymphocyte count, no. x 10 ⁹ (IQR)	2.1 (1.65-2.74)	2.13 (1.18-2.58)	0.773
Serum glycaemia, mg/dL (IQR)	116 (103-166)	107 (91-130)	0.096
INR [*] , no. (IQR)	1.08 (1.01-1.13)	1.13 (1.02-1.28)	0.098
Clinical/ radiological			
Time window to CT [†]			0.214
0-3 hours, no. (%)	24 (77.4)	21 (87.5)	
3-6 hours, no. (%)	7 (22.6)	2 (8.3)	
6-8 hours, no. (%)	0 (0.0)	1 (4.2)	
TOAST [‡] classification			
Atherothrombotic, no. (%)	19 (61.3)	13 (54.2)	
Cardio-embolic, no. (%)	12 (38.7)	11 (45.8)	0.783
Intravenous r-tPA [§] , no (%)	21 (67.7)	18 (75.0)	0.765
NIHSS	11 (7-20)	10 (7-14)	0.208

Comparison were drawn by Mann-Whitney U test, Fisher's exact test or Kruskal-Wallis test, as appropriate. Data are expressed as median (interquartile range [IQR]) or number [no.] (percentages [%]).

WBC: white blood cells

* INR: international normalized ratio

† CT: computerized tomography

‡ TOAST: Trial of Org 10172 in Acute Stroke Treatment

§ r-tPA: recombinant tissue plasminogen activation

|| NIHSS: National Institutes of Health Stroke Scale

MTT: mean-transit-time

** CBV: cerebral blood volume

Table 4. Multiple linear regression for predicting the reduction of ischemic lesion volume at day 1 and the final infarct at day 90.

	B (95% CI)	β	p-value
Volume lesion reduction			
Age	-0.069 (-0.640-0.502)	-0.019	0.809
Gender, male	7.361 (-8.481-23.202)	0.073	0.354
Glycemia	-0.105 (-0.324-0.115)	0.109	0.341
Time window to CT [#]	-4.948 (-23.525-13.628)	-0.044	0.594
Intravenous r-tPA [*]	-2.095 (-21.594-17.404)	-0.019	0.830
NIHSS [†] at onset	-0.139 (-1.753-1.475)	-0.016	0.863
Ischemic core volume	0.554 (0.290-0.819)	0.334	<0.001
Ischemic penumbra	0.663 (0.496-0.830)	0.587	<0.001
Reperfusion at day 1	46.803 (29.138-64.469)	0.461	<0.001
Recanalization at day 1	29.425 (6.271-52.580)	0.265	0.014
Final infarct volume			
Age	-0.851 (-41.309-191.681)	-0.142	0.180
Gender, male	-22.466 (-57.409-12.477)	-0.139	0.202
Glycemia	-0.058 (-0.542-0.426)	-0.027	0.809
Time window to CT	42.518 (1.540-893.945)	0.233	0.042
Intravenous r-tPA	22.079 (-20.931-65.090)	0.124	0.307
NIHSS at onset	2.289 (-1.271-5.849)	0.163	0.202
Ischemic core volume	1.270 (0.687-1.854)	0.476	<0.001
Ischemic penumbra	-0.060 -(0.428-0.308)	0.033	0.745
Reperfusion at day 1	-54.236 (-93.203- -15.270)	-0.333	0.007
Recanalization at day 1	-1.606 (-52.681-49.469)	-0.009	0.950

Volume of lesion growth is defined as the Δ baseline-day 1.

CT: computerized tomography WBC: white blood cells

* r-tPA: recombinant tissue plasminogen activator

† NIHSS: National Institutes of Health Stroke Scale

Table 5. Multiple logistic regression for predicting good clinical response at day 1 (reduction of ≥ 8 points on the NIHSS or a NIHSS score ≤ 1), occurrence of hemorrhagic transformation and good functional outcome (modified Rankin Scale, 0-1) at day 90.

	OR (95% CI)	p-value
Good clinical response (day 1)		
Age	1.090 (1.002-1.185)	0.044
Gender, male	3.316 (0.475-23.150)	0.227
Glycemia	0.928 (0.870-0.990)	0.024
Time window to CT [#]	1.751 (0.108-28.333)	0.693
Intravenous r-tPA [*]	0.746 (0.056-9.940)	0.825
NIHSS [†] at onset	1.235 (0.978-1.559)	0.076
Ischemic core volume	0.946- (0.898-0.996)	0.034
Ischemic penumbra	1.002 (0.982-1.023)	0.811
Recanalization at day 1	7.721 (0.296-201.188)	0.219
Reperfusion at day 1 $\geq 75\%$	16.054 (1.423-181.158)	0.025
Hemorrhagic transformation (onset-day 7)		
Age	1.014 (0.941-1.092)	0.720
Gender, male	0.476 (0.076-2.976)	0.427
Glycemia	1.020 (0.998-1.042)	0.076
Time window to CT	0.156 (0.007-3.573)	0.245
Intravenous r-tPA	1.197 (0.119-12.010)	0.879
NIHSS at onset	1.052 (0.862-1.284)	0.616
Ischemic core volume	1.074 (1.007-1.147)	0.030
Ischemic penumbra	1.000 (0.981-1.019)	0.984
Recanalization at day 1	0.744 (0.065-8.575)	0.812
Reperfusion at day 1 $\geq 75\%$	0.153 (0.022-1.047)	<u>0.056</u>
Good functional outcome (day 90)		
Age	0.950 (0.854-1.058)	0.0351
Gender, male	0.348 (0.035-3.471)	0.370
Glycemia	0.968 (0.939-0.998)	0.034
Time window to CT	0.071 (0.004-1.347)	0.078
Intravenous r-tPA	0.050 (0.002-1.054)	0.054
NIHSS at onset	0.734 (0.569-0.949)	0.018
Ischemic core volume	0.964 (0.922-1.007)	0.095
Ischemic penumbra	1.008 (0.985-1.032)	0.507
Recanalization at day 1	1.618 (0.178-14.700)	0.669
Reperfusion at day 1 $\geq 75\%$	25.801 (1.483-448.840)	0.026

CT: computerized tomography WBC: white blood cells

* r-tPA: recombinant tissue plasminogen activator

† NIHSS: National Institutes of Health Stroke Scale